We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

142 hedge funds and large institutions have $1.34B invested in Zentalis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,075% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $36K

157% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 14

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

18% more funds holding

Funds holding: 120 → 142 (+22)

13% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 38

9% more capital invested

Capital invested by funds: $1.24B → $1.34B (+$107M)

4.78% more ownership

Funds ownership: 115.41% → 120.2% (+4.8%)

Holders
142
Holders Change
+22
Holders Change %
+18.33%
% of All Funds
2.05%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
36
Increased
43
Reduced
38
Closed
14
Calls
$1.14M
Puts
$36K
Net Calls
+$1.11M
Net Calls Change
-$15.4M

Top Buyers

1
MB
MPM BioImpact
Massachusetts
+$20.9M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$13.4M
3
Verition Fund Management
Verition Fund Management
Connecticut
+$11.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$8.06M
5
PBA
Paradigm Biocapital Advisors
New York
+$7.5M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$13.1M
2
State Street
State Street
Massachusetts
-$8.68M
3
IHAM
Integral Health Asset Management
New York
-$3.79M
4
Bank of America
Bank of America
North Carolina
-$3.34M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$220M – – –
EAM
2
Eventide Asset Management
Massachusetts
$182M +$204K +14,846 +0.1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$168M +$4.22M +307,053 +3%
BlackRock
4
BlackRock
New York
$73.2M -$539K -39,217 -0.8%
Vanguard Group
5
Vanguard Group
Pennsylvania
$69.3M -$13.1M -951,833 -18%
Citadel Advisors
6
Citadel Advisors
Florida
$60.7M +$2.35M +170,647 +5%
State Street
7
State Street
Massachusetts
$59.7M -$8.68M -631,404 -14%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$55M +$8.06M +585,644 +20%
T. Rowe Price Investment Management
9
T. Rowe Price Investment Management
Maryland
$52.3M +$13.4M +977,303 +42%
Capital International Investors
10
Capital International Investors
California
$44.4M – – –
DC
11
Decheng Capital
California
$33.1M – – –
Federated Hermes
12
Federated Hermes
Pennsylvania
$31.5M -$2.23M -161,865 -7%
MB
13
MPM BioImpact
Massachusetts
$23.9M +$20.9M +1,516,183 New
WP
14
Woodline Partners
California
$22.6M +$460K +33,473 +2%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$20.5M +$667K +48,500 +4%
Primecap Management
16
Primecap Management
California
$18.4M +$1.94M +141,260 +14%
Verition Fund Management
17
Verition Fund Management
Connecticut
$18.2M +$11.1M +810,619 +235%
Morgan Stanley
18
Morgan Stanley
New York
$16.3M -$2.5M -181,557 -15%
TCM
19
Tybourne Capital Management
Hong Kong
$15.2M – – –
PBA
20
Paradigm Biocapital Advisors
New York
$14.9M +$7.5M +544,917 +136%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$11.4M -$5.19K -377 -0.1%
Northern Trust
22
Northern Trust
Illinois
$8.25M -$86.7K -6,301 -1%
5VM
23
5AM Venture Management
California
$7.72M – – –
Bank of America
24
Bank of America
North Carolina
$7.5M -$3.34M -242,687 -34%
Charles Schwab
25
Charles Schwab
California
$7.19M +$139K +10,114 +2%
1
2 3 4 5

ZNTL Hedge Fund Activity: Q1 2024 in Review

142 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2024, worth a combined $1.34B — up 8.6% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ZNTL positions and 14 closed out — a net gain of 22 holders — while 43 added to existing stakes and 38 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $20.9M. The largest seller was Vanguard Group, cutting an estimated $13.1M.

  • 142 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2024, up from 120 in Q4 2023.
  • Funds reported $1.34B of Zentalis Pharmaceuticals stock for Q1 2024, up 8.6% quarter-over-quarter.
  • 36 funds opened new Zentalis Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +22 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2024 was MPM BioImpact, an estimated $20.9M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2024 was Vanguard Group, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2024.